Teladoc Health (NYSE:TDOC) Shares Gap Up Following Analyst Upgrade

Teladoc Health, Inc. (NYSE:TDOC)’s stock price gapped up before the market opened on Tuesday after Deutsche Bank Aktiengesellschaft upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $5.30, but opened at $6.01. Deutsche Bank Aktiengesellschaft now has a $11.00 price target on the stock. Teladoc Health shares last traded at $5.5870, with a volume of 4,264,206 shares traded.

Other analysts have also recently issued reports about the stock. TD Cowen dropped their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. Leerink Partners lowered their target price on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a report on Thursday, February 26th. Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 price target (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. Finally, Canaccord Genuity Group reduced their price target on Teladoc Health from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.76.

Insider Buying and Selling

In related news, CEO Charles Divita III sold 17,138 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.58% of the company’s stock.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Deutsche Bank upgraded TDOC from Hold to Buy and set an $11 price target (roughly ~97% above the recent price), explicitly citing valuation as the reason for the upgrade. This is the main catalyst for renewed buying interest. Teladoc jumps as Deutsche Bank upgrades
• Positive Sentiment: Analysts pointed to a “compelling” valuation after TDOC’s Talkspace-related transaction/partnership as supporting upside, which helped spark a ~10% pre-market pop in some headlines. That narrative (value + deal optionality) is driving short-term buying. TDOC stock surges 10% pre-market, analyst cites ‘compelling’ valuation after Talkspace deal
• Positive Sentiment: Market write-ups and analyst notes (Benzinga, 247WallSt) are echoing the same view—strategic partnerships and business pivots are reshaping TDOC’s risk/reward and prompting fresh buy-side interest. Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
• Neutral Sentiment: Management presented at the Barclays 28th Annual Global Healthcare Conference (transcript available). Presentations can provide greater visibility on strategy and cost plans but don’t always change near-term fundamentals unless guidance or new deals are announced. Teladoc Health, Inc. (TDOC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Allianz Asset Management GmbH boosted its stake in Teladoc Health by 189.2% during the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock valued at $12,518,000 after buying an additional 1,059,458 shares during the period. Vanguard Group Inc. increased its stake in Teladoc Health by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock worth $169,372,000 after acquiring an additional 891,732 shares during the last quarter. Jupiter Asset Management Ltd. purchased a new stake in shares of Teladoc Health in the 3rd quarter valued at about $7,576,000. Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in shares of Teladoc Health by 23.1% in the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 212,933 shares of the health services provider’s stock valued at $1,841,000 after acquiring an additional 39,956 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of Teladoc Health during the 2nd quarter valued at about $5,040,000. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Trading Up 5.5%

The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.67 and a current ratio of 2.77. The stock has a market cap of $997.26 million, a P/E ratio of -4.90 and a beta of 2.13. The stock has a 50-day moving average price of $5.72 and a 200-day moving average price of $7.09.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The company had revenue of $642.27 million for the quarter, compared to analysts’ expectations of $635.33 million. During the same period in the prior year, the business earned ($0.28) earnings per share. Teladoc Health’s revenue for the quarter was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, equities research analysts expect that Teladoc Health, Inc. will post -1.16 EPS for the current year.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.